Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Petrelintide for Weight Loss in Overweight or Obese Patients with Related Health Issues

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment called Petrelintide for individuals who are obese or overweight and have related health issues. The treatment involves a solution for injection that is administered under the skin. The study will compare the effects of different doses of Petrelintide to a placebo, which is a substance with no active medication, to see how they affect body weight when combined with a reduced-calorie diet and increased physical activity.

The main goal of the study is to understand how different doses of Petrelintide can help reduce body weight over a period of 28 weeks. Participants will receive injections once a week and will be monitored to see how their body weight changes. The study will also look at whether participants can achieve a weight loss of 5% or 10% from their starting weight by the end of the study period.

This trial is designed to help researchers find the most effective dose of Petrelintide for managing weight in people with obesity or overweight conditions. Participants will be asked to follow a specific diet and exercise plan while receiving the treatment. The study aims to provide valuable information on how Petrelintide can be used as a part of a weight management program.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial trial phase

    Upon joining the trial, participants will begin by receiving a solution for injection containing either petrelintide or a placebo. The injection is administered subcutaneously, which means it is given under the skin.

    The trial is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the active medication or the placebo.

  2. Step 2

    Medication administration

    Participants will receive the injection once a week for a total duration of 28 weeks.

    The purpose of the trial is to evaluate the effect of different doses of petrelintide on body weight when combined with a reduced-calorie diet and increased physical activity.

  3. Step 3

    Diet and activity adjustments

    Participants are expected to follow a reduced-calorie diet and engage in increased physical activity throughout the trial period.

    These lifestyle changes are essential components of the trial and are intended to complement the effects of the medication.

  4. Step 4

    Monitoring and assessments

    Throughout the trial, participants will be monitored for changes in body weight.

    The primary goal is to observe the percentage change in body weight from the start of the trial to the end of the 28-week period.

  5. Step 5

    Completion of trial

    At the end of the 28 weeks, the trial will assess whether participants have achieved a body weight loss of at least 5% or 10% from their initial weight.

    The trial is expected to conclude by July 6, 2026.

Who can join the trial?

5 criteria

  • You must sign a form to show you understand and agree to participate in the study before any study-related activities begin.
  • You need to be at least 18 years old when you sign the consent form.
  • Your Body Mass Index (BMI) should be 30.0 or higher. If your BMI is 27.0 or higher, you must also have at least one of these conditions: hypertension (high blood pressure) or dyslipidemia (abnormal cholesterol levels), whether treated or not, as decided by the study doctor.
  • Both men and women can participate. If you are a woman, you can join if you are not able to have children or if you can have children but are not pregnant, do not plan to become pregnant, are not breastfeeding, and agree to use effective birth control methods during the study and for 10 weeks after the last study injection.
  • You must be able to follow the study rules, including giving yourself the study medication using a vial and syringe.

Who cannot join the trial?

3 criteria

  • Individuals who are not able to follow a reduced-calorie diet and increased physical activity plan.
  • Individuals who are not within the specified age range for the study.
  • Individuals who are part of a vulnerable population, which means they might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Petrelintide is a medication being studied for its potential to help people with obesity or overweight who have weight-related health issues. The trial is investigating how different doses of this medication affect body weight when combined with a reduced-calorie diet and increased physical activity over a period of 28 weeks.

What is already known about the treatment

Petrelintide – This medication is administered as an injection, typically given once a week. It is currently being studied in clinical trials for its effectiveness in managing weight in individuals who are obese or overweight, especially those with related health issues. Petrelintide works by influencing certain hormones in the body that regulate appetite and metabolism, helping to reduce body weight when combined with a low-calorie diet and increased physical activity. It is classified as a weight management drug and is still under investigation to determine its full potential and safety profile.

Investigated diseases

Obesity – Obesity is a condition characterized by excessive body fat accumulation that may negatively impact health. It develops when calorie intake consistently exceeds calorie expenditure, leading to weight gain. Over time, this can result in increased body mass index (BMI) and may contribute to various health issues. The progression of obesity can be influenced by factors such as genetics, lifestyle, and environmental factors. It often requires long-term lifestyle changes to manage effectively.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-512549-18-00Protocol codeZP8396-23094Estimated enrolment493 patientsSponsorZealand Pharma A/S

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).